We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
-3.14%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$52.8B
AUM Growth
-$1.34B
Cap. Flow
+$1.39B
Cap. Flow %
2.62%
Top 10 Hldgs %
12%
Holding
4,607
New
780
Increased
956
Reduced
789
Closed
1,336

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$532M
2
WFC icon
Wells Fargo
WFC
+$480M
3
V icon
Visa
V
+$435M
4
VZ icon
Verizon
VZ
+$320M
5
AVGO icon
Broadcom
AVGO
+$273M

Sector Composition

Rank Sector Weight
1 Financials 18.66%
2 Technology 16.35%
3 Healthcare 16.13%
4 Consumer Discretionary 11.2%
5 Industrials 7.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LVAC
2701
DELISTED
LAVA Medtech Acquisition Corp. Class A Common Stock
LVAC
$563K ﹤0.01%
+56,541
New +$561K
CAE icon
2702
CAE Inc. Common Shares
CAE
$8.56B
$560K ﹤0.01%
+21,484
New +$546K
AVXL icon
2703
Anavex Life Sciences
AVXL
$235M
$558K ﹤0.01%
+45,358
New +$558K
IYK icon
2704
iShares US Consumer Staples ETF
IYK
$1.44B
$556K ﹤0.01%
+8,328
New +$555K
OHI icon
2705
Omega Healthcare
OHI
$15.3B
$555K ﹤0.01%
+17,817
New +$525K
REVEW
2706
CALL
DELISTED
Alpine Acquisition Corp Warrant
REVEW
$555K ﹤0.01%
55,079
ATEN icon
2707
A10 Networks
ATEN
$2.13B
$553K ﹤0.01%
39,679
+35,974
+971% +$506K
PPLI
2708
People Inc
PPLI
$3.15B
$553K ﹤0.01%
6,733
-19,534
-74% -$1.9M
BCEL
2709
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$551K ﹤0.01%
+173,759
New +$421K
KRON
2710
DELISTED
Kronos Bio
KRON
$550K ﹤0.01%
+76,069
New +$649K
OHPAW
2711
CALL
DELISTED
Orion Acquisition Corp. Warrant
OHPAW
$550K ﹤0.01%
56,245
CCC
2712
CCC Intelligent Solutions
CCC
$3.62B
$548K ﹤0.01%
49,719
-61,232
-55% -$642K
TUR icon
2713
CALL
iShares MSCI Turkey ETF
TUR
$202M
$548K ﹤0.01%
+26,500
New +$522K
SKYY icon
2714
First Trust Cloud Computing ETF
SKYY
$2.89B
$547K ﹤0.01%
6,039
-24,415
-80% -$2.19M
LPG icon
2715
Dorian LPG
LPG
$1.97B
$543K ﹤0.01%
37,543
-103,347
-73% -$1.37M
ZEPP
2716
Zepp Health
ZEPP
$65.7M
$543K ﹤0.01%
+46,978
New +$759K
PXI icon
2717
Invesco Dorsey Wright Energy Momentum ETF
PXI
$58.8M
$542K ﹤0.01%
+12,685
New +$471K
CCS icon
2718
Century Communities
CCS
$2B
$541K ﹤0.01%
10,090
-43,961
-81% -$2.82M
GNK icon
2719
Genco Shipping & Trading
GNK
$1.1B
$541K ﹤0.01%
22,888
+13,223
+137% +$245K
OCGN icon
2720
Ocugen
OCGN
$403M
$540K ﹤0.01%
+163,555
New +$575K
TBBK icon
2721
The Bancorp
TBBK
$2.82B
$539K ﹤0.01%
19,031
+12,126
+176% +$349K
THRM icon
2722
Gentherm
THRM
$1.33B
$539K ﹤0.01%
7,381
-30,563
-81% -$2.54M
ORIAW
2723
CALL
DELISTED
Orion Biotech Opportunities Corp. Warrant
ORIAW
$538K ﹤0.01%
54,995
KALV
2724
DELISTED
KalVista Pharmaceuticals
KALV
$536K ﹤0.01%
+36,359
New +$522K
QTEC icon
2725
First Trust NASDAQ-100 Technology Index Fund
QTEC
$4.45B
$532K ﹤0.01%
+3,492
New +$532K

Similar funds

Marshall Wace's Q1 2022 Portfolio in Review

As of Q1 2022, Marshall Wace held 4,607 positions worth $52.8B, down 2.5% from $54.2B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Marshall Wace's Q1 2022 filing shows 780 new, 956 increased, 789 reduced and 1,336 closed positions. Its largest new stake was Agilent Technologies: 1,082,487 shares worth $143M. The largest sale was Microsoft, an estimated $547M.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 16% a quarter earlier, followed by Technology and Healthcare.

  • Marshall Wace's largest Q1 2022 buy was Agilent Technologies: 1,082,487 shares worth $143M.
  • Marshall Wace added most to Merck in Q1 2022, an estimated $532M increase.
  • Marshall Wace's biggest Q1 2022 reduction was Microsoft, cutting an estimated $547M.
  • Marshall Wace fully exited Elevance Health in Q1 2022, selling an estimated $226M.
  • Marshall Wace's ten largest holdings make up 12% of its $52.8B portfolio in Q1 2022.
  • Marshall Wace opened 780 new positions and closed 1,336 in Q1 2022.
  • Marshall Wace's portfolio value fell 2.5% quarter-over-quarter to $52.8B.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.